Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 18/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 17/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19826456 | 0.86 | CYP11B2 (0.48) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL301704 | 0.82 | TRPV4 (0.43) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL769392 | 0.78 | MAOB (0.42) | TRPV4 | |
| SCHEMBL15540252 | 0.77 | TRPV4 (0.33) | TRPV4 | |
| SCHEMBL30919072 | 0.76 | TRPV4 (0.61) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL57346 | 0.76 | TRPV4 (0.61) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL18297999 | 0.76 | CYP11B2 (0.67) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL21687452 | 0.76 | TRPV4 (0.35) | TRPV4 | |
| SCHEMBL9612021 | 0.74 | CYP11B2 (0.68) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL1797379 | 0.74 | TRPV4 (0.59) | TRPV4CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111511725-B | 1-cyano-2- (4-cyclopropyl-benzyl) -4-) (beta-D-glucopyranos-1-yl) -benzene Synthesis of 1:1:1 Co-crystals of L-proline and Water | 勃林格殷格翰维特梅迪卡有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-11225500-B2 | Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, L-proline and water | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-01-18 | — | — | US | claimed |
| US-20210139520-A1 | SYNTHESIS OF 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, L-PROLINE AND WATER | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2021-05-13 | — | — | US | claimed |
| CN-111511725-A | Synthesis of 1:1:1 cocrystals of 1-cyano-2- (4-cyclopropyl-benzyl) -4- (β -D-glucopyranos-1-yl) -benzene, L-proline and water | 勃林格殷格翰维特梅迪卡有限公司 | 2020-08-07 | — | — | CN | claimed |
| EP-3668846-A1 | SYNTHESIS OF THE 1 :1 :1 CO-CRYSTAL OF 1 -CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(BETA-D-GLUCOPYRANOS-1 -YL)-BENZENE, L-PROLINE AND WATER | Boehringer Ingelheim Vetmedica GmbH (DE) | 2020-06-24 | — | — | EP | claimed |
| JP-4128258-A | — | — | None | — | — | JP | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-119661371-A | Preparation method of 2-fluoro-4-methylaniline | 帕潘纳(北京)科技有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| EP-4501912-A1 | NOVEL HETEROCYCLIC COMPOUND | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| CN-118475560-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-101360713-A | 6- (polysubstituted aryl) -4-aminopicolinates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2009-02-04 | — | — | CN | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| WO-2009012275-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| CN-101326184-A | Bis-heterocyclic imidazolyl compounds | SPEEDEL EXPERIMENTA AG (CH) | 2008-12-17 | — | — | CN | disclosed |
| EP-0442266-B1 | Tolan derivatives, liquid crystal compositions containing them, and liquid crystal elements using them | SEIKO EPSON CORP (JP) | 1994-12-28 | — | — | EP | disclosed |
| US-5314640-A | Tolan derivatives, liquid crystal compositions including same, liquid crystal display devices including the compositions and method of preparation | SEIKO EPSON CORPORATION (JP) | 1994-05-24 | — | — | US | disclosed |
| JP-H04128258-A | TOLAN DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME DERIVATIVE AND LIQUID CRYSTAL ELEMENT USING THE SAME COMPOSITION | SEIKO EPSON CORP | 1992-04-28 | — | — | JP | disclosed |
| EP-0442266-A1 | Tolan derivatives, liquid crystal compositions containing them, and liquid crystal elements using them | SEIKO EPSON CORPORATION (JP) | 1991-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225500-B2 | Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, L-proline and water | COL1A1, DCXR, PLOD1 | TRPV4 3767/4885CYP11B2 2222/4885CYP11B1 1294/4885 |
| US-20210139520-A1 | SYNTHESIS OF 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, L-PROLINE AND WATER | COL1A1, DCXR, PLOD1 | TRPV4 3741/4885CYP11B2 2219/4885CYP11B1 1289/4885 |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | TRPV4 4257/4885CYP11B2 600/4885CYP11B1 1153/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | TRPV4 2728/4885CYP11B2 9/4885CYP11B1 48/4885 |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | TRPV4 506/4885CYP11B2 1057/4885CYP11B1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.